Phosplatin Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Phosplatin Therapeutics's estimated annual revenue is currently $4.2M per year.
- Phosplatin Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Phosplatin Therapeutics has 27 Employees.
- Phosplatin Therapeutics grew their employee count by 0% last year.
Phosplatin Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VICE PRESIDENT OF FINANCE & ADMINISTRATION | Reveal Email/Phone |
2 | VICE PRESIDENT OF COMMERCIALIZATION | Reveal Email/Phone |
3 | Interim Chief Medical Officer | Reveal Email/Phone |
4 | President/CEO | Reveal Email/Phone |
Phosplatin Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Phosplatin Therapeutics?
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers. Phosphaplatins are the result of over 20 years of work by the inventor, and uniquely combine an immunological form of apoptosis with an attractive safety profile. The lead agent is the subject of two approved IND applications with the US FDA, and of a collaboration and option agreement for rights in Greater China with SciClone Pharmaceuticals. Website: www.phosplatin.com
keywords:N/A
N/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Phosplatin Therapeutics News
Phosplatin Therapeutics Inc., a clinical-stage pharmaceutical company, ... trial of the company's lead therapeutic candidate, PT-112.
Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR...
Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.8M | 27 | 0% | $365.3M |
#2 | $4.3M | 27 | -34% | N/A |
#3 | $2.7M | 27 | -53% | N/A |
#4 | $3.9M | 27 | -4% | N/A |
#5 | $1.9M | 27 | -4% | N/A |